RxDoctor Payments Data

Amirtha Ajit, MD

Internal Medicine · Anaheim, CANPI 1881688422

Payments from drug & device makers

$890in general payments, 2019–2025

Across 42 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$208
  • AstraZeneca$170
  • Pfizer$77
  • Boehringer Ingelheim$66
  • GSK$66
  • Novo Nordisk$61
  • plus $243 from 8 others

What the payments were for

  • Food & beverage$87999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$78,077
Medicare patients
190
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$102,042
JardianceEmpagliflozin82$94,844
EliquisApixaban58$77,536
TrulicityDulaglutide24$35,642
FarxigaDapagliflozin Propanediol34$35,145
JanuviaSitagliptin Phosphate26$28,999
MyrbetriqMirabegron41$22,391
JanumetSitagliptin Phos/Metformin Hcl20$20,471
LinzessLinaclotide21$16,918
VascepaIcosapent Ethyl44$13,699
ZenpepLipase/Protease/Amylase13$12,134
Breo ElliptaFluticasone/Vilanterol12$11,564
XareltoRivaroxaban12$9,614
Levothyroxine Sodium414$5,797
Metformin Hcl207$5,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$102,04275 claims
Boehringer IngelheimJardiance$66$94,84482 claims
PfizerEliquis$77$77,53658 claims
Lilly USA, LLCTrulicity$16$35,64224 claims
AstraZenecaFarxiga$170$35,14534 claims
Astellas Pharma US IncMyrbetriq$44$22,39141 claims
AbbVieLinzess, Synthroid$56$19,96361 claims
GSKBreo Ellipta$66$11,56412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →